Elyxium Wealth LLC Has $640,000 Holdings in Pfizer Inc. (NYSE:PFE)

Elyxium Wealth LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 108.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,246 shares of the biopharmaceutical company's stock after purchasing an additional 13,144 shares during the quarter. Elyxium Wealth LLC's holdings in Pfizer were worth $640,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in PFE. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth $27,000. Gould Capital LLC lifted its holdings in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares in the last quarter. North Capital Inc. acquired a new stake in shares of Pfizer during the first quarter worth $28,000. Bernard Wealth Management Corp. acquired a new position in Pfizer in the fourth quarter valued at about $30,000. Finally, Horizon Financial Services LLC acquired a new position in Pfizer in the first quarter valued at about $35,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Price Performance

Shares of NYSE:PFE opened at $24.46 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The stock's 50 day moving average is $24.07 and its 200-day moving average is $24.73. The firm has a market capitalization of $139.06 billion, a price-to-earnings ratio of 17.72, a PEG ratio of 0.89 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same period in the prior year, the firm posted $0.82 EPS. Pfizer's quarterly revenue was down 7.8% compared to the same quarter last year. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.03%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent analyst reports. Wolfe Research lifted their target price on Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a research report on Wednesday, April 30th. Redburn Atlantic lowered their target price on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research note on Wednesday, April 30th. Leerink Partners lowered their target price on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research note on Wednesday, April 30th. HSBC lowered their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Finally, TD Cowen lowered their target price on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research note on Tuesday, April 22nd. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $28.55.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.